Macrocyclic peptides are promising for pharmaceuticals for cancer—however, screening for them is challenging. Findings were published in the journal Angewandte Chemie.
"Well-established screening approaches often require highly expensive instrumentation and appropriate training," says Ashram Brik from the Technion-Israel Institute of Technology, Israel, who is set up to develop alternative strategies.
Learn more about peptide based-drugs:
"For example, we subjected the peptides to chemistries such as alkylation arylation, oxidation and dimerization, the first step to make polycyclic peptides," Brik said. "Polycyclic peptides have added value crucial to be considered as drug candidates." Scientists assume that cyclization makes the peptides more stable than their open analogues, and their compact shapes help them to enter cells more easily.
Source: Science Daily
